The deposition of beta-amyloid and tau proteins is considered a defining feature of Alzheimer's disease and has therefore been the target of therapeutic drug development.
In this ReCAP, Dr Pierre Tariot discusses several anti-amyloid therapies, including aducanumab and lecanemab, which were recently approved for the treatment of Alzheimer's disease. He considers their potential for slowing disease progression as well as lowering the risk for amyloid-related imaging abnormalities.
Finally, he discusses emerging therapies for Alzheimer's disease that are currently in clinical trials, including donanemab, and considers potential development of nonamyloid, non-tau therapeutic strategies.
Medscape © 2023 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Emerging Therapies for Alzheimer's Disease - Medscape - Apr 28, 2023.
Comments